Posts

Efficacy of cannabidiol treatment in experimental MS is due to immunosuppressive activity of myeloid cells in CNS downregulating recruitment of CD4+ T cells, proinflammatory chemokines and gasdermin D expression

/by

Authors: Nicholas Dopkins, Kiesha Wilson, Kathryn Miranda, Prakash S Nagarkatti and Mitzi Nagarkatti Published in The Journal of Immunology May 2020   Abstract Cannabidiol (CBD) is a nonpsychoactive ingredient from Cannabis that has garnered attention in the medical community due to its anti-inflammatory properties and therapeutic potential. CBD has in particular become a popular alternative…

Read more

Cannabidiol for psychosis: A review of 4 studies

/by

Authors: Sy Atezaz Saeed, MD, MS, and Kathryn E. Clary, BA Published in Current Psychiatry June 2020   Introduction There has been increasing interest in the medicinal use of cannabidiol (CBD) for a wide variety of health conditions. CBD is one of more than 80 chemicals identified in the Cannabis sativa plant, otherwise known as…

Read more

Cannabidiol: Assessing preclinical safety in ovarian and endometrial carcinoma cell lines

/by

Authors: Shannon Rush, Arvinder K Kapur, Manish S. Patankar, Lisa Marie Barroilhet Published in Journal of Clinical Oncology May 2020   Abstract Background: Cancer patients use cannabidiol (CBD) for chemotherapy and cancer symptoms, though research of CBD safety and efficacy for these conditions are ongoing and mixed. We sought to determine endometrial (ECC1) and epithelial…

Read more

Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials.

/by

Authors: Rafael G. dos Santos, Francisco S. Guimarães, José Alexandre S. Crippa, et al
Expert Opinion on Drug Metabolism & Toxicology, 9 April 2020
—
Introduction: Recent trials using cannabidiol (CBD) have shown that most acute and prolonged adverse effects of CBD are mild to moderate, with rare serious adverse effects (SAEs). This review focused on analyzing SAEs of CBD and their possible relation to drug-drug interaction…

Read more

Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials.

/by

Authors: Edward Chesney, Dominic Oliver, Alastair Green, Simina Sovi, Jack Wilson, Amir Englund, et al
Neuropsychopharmacology, 8 April 2020
—
Cannabidiol (CBD) is being investigated as a treatment for several medical disorders but there is uncertainty about its safety. We conducted the first systematic review and meta-analysis of the adverse effects of CBD across all medical indications. Double-blind randomized plac…

Read more

The Effect of Piperine on Oral Absorption of Cannabidiol following Acute vs. Chronic Administration.

/by

Authors: Dvora Izgelov, Abraham J. Domb, Amnon Hoffman
European Journal of Pharmaceutical Sciences, 17 March 2020
—
The piperine is an alkaloid naturally found mostly in black pepper with a myriad of pharmacological attributes. The most far reaching indication of piperine is its use as an absorption enhancer, with supportive data regarding piperine’s ability to inhibit first pass effect mec…

Read more

Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol.

/by

Authors: Patrycja Bielawie, Ewa Harasim-Symbor, Adrian Chabowski
Frontiers in Endocrinology, 4 March 2020
—
Currently, an increasing number of diseases related to insulin resistance and obesity is an alarming problem worldwide. It is well-known that the above states can lead to the development of type 2 diabetes, hypertension, and cardiovascular diseases. An excessive amount of tria…

Read more

Cannabinoids and hormone receptor-positive breast cancer treatment.

/by

Authors: Luka Dobovišek, Fran Krstanović, Simona Borštnar, Nataša Debeljak
Cancers, 25 February 2020
—
Breast cancer (BC) is the most common cancer in women worldwide. Approximately 70-80% of BCs express estrogen receptors (ER), which predict the response to endocrine therapy (ET), and are therefore hormone receptor-positive (HR+). Endogenous cannabinoids together with cannabin…

Read more

Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement.

/by

Authors: B. Whitcomb, C. Lutman, M. Pearl, E. Medlin, E. Prendergast, K. Robison, W. Burke
Gynecologic Oncology, 10 January 2020
—
Tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) affect the human endocannabinoid system. Cannabinoids reduce chemotherapy induced nausea or vomiting (CINV) and neuropathic pain. Each state has its own regulations for medical and recreational cannabis use. Ef…

Read more

Cannabinoids and the expanded endocannabinoid system in neurological disorders.

/by

Authors: Luigia Cristino, Tiziana Bisogno, Vincenzo Di Marzo
Nature Reviews Neurology, January 2020
—
Anecdotal evidence that cannabis preparations have medical benefits together with the discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated efforts to develop cannabinoid-based therapeutics. These efforts have been marked by disappointment, es…

Read more

Indications and administration practices amongst medical cannabis healthcare providers: a cross-sectional survey.

/by

A study published in BMC Family Practice sought to characterize the clinical practice characteristics of medical professionals who recommend cannabis.

Read more

The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities.

/by

Authors: Dixon H. Xu, Benjamin D. Cullen, Meng Tang, Yujiang Fang
Current Pharmaceutical Biotechnology, December 2019
—
BACKGROUND: Peripheral neuropathy can significantly impact the quality of life for those who are affected, as therapies from the current treatment algorithm often fail to deliver adequate symptom relief. There has, however, been an increasing body of evidence for the use of ca…

Read more